Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
March 13, 2024
When world leaders gather in September for this year’s UN General Assembly, antimicrobial resistance (AMR) will be on the agenda. For people like me who care passionately about this issue, this is a welcome opportunity to address a global problem with a global solution. Ahead of September, we need t...
Blog Post
February 22, 2024
The process of discovering, producing, buying, and consuming antibiotics is riddled with market and government failures. To solve antibiotic resistance, it’s not enough to solve just some of these. If we fix the market failures that reduce the number of new antibiotics that are discovered, but not t...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 21, 2023
The politics of antimicrobial resistance (AMR) has changed substantially since we launched the first CGD working group on AMR in 2007. There is now much more awareness about the need to act, even if global solutions have not yet been implemented. Countries including the UK, Canada, and Japan have an...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...